West Pharmaceutical Services (WST) Receives Coverage Optimism Rating of 0.16
Media headlines about West Pharmaceutical Services (NYSE:WST) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. West Pharmaceutical Services earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 46.9239775185692 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Shares of West Pharmaceutical Services (NYSE:WST) traded down $1.35 during mid-day trading on Friday, hitting $97.74. 414,340 shares of the stock traded hands, compared to its average volume of 245,454. The company has a market cap of $7,257.49, a P/E ratio of 38.94, a price-to-earnings-growth ratio of 2.00 and a beta of 1.11. West Pharmaceutical Services has a 12-month low of $77.97 and a 12-month high of $103.36. The company has a quick ratio of 1.87, a current ratio of 2.59 and a debt-to-equity ratio of 0.15.
West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.53 by $0.14. The firm had revenue of $398.20 million for the quarter, compared to the consensus estimate of $386.02 million. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. The company’s revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm earned $0.53 EPS. equities analysts expect that West Pharmaceutical Services will post 2.76 earnings per share for the current year.
WST has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Bank of America downgraded shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective on the stock. in a research report on Tuesday, October 17th. Wells Fargo & Co raised their price objective on shares of West Pharmaceutical Services from $105.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Finally, Stephens initiated coverage on shares of West Pharmaceutical Services in a research report on Tuesday, October 3rd. They set an “equal weight” rating and a $99.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. West Pharmaceutical Services currently has a consensus rating of “Hold” and an average price target of $106.00.
In other West Pharmaceutical Services news, CFO William J. Federici sold 21,000 shares of West Pharmaceutical Services stock in a transaction on Friday, December 8th. The shares were sold at an average price of $99.01, for a total value of $2,079,210.00. Following the sale, the chief financial officer now directly owns 190,493 shares in the company, valued at approximately $18,860,711.93. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 1.90% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “West Pharmaceutical Services (WST) Receives Coverage Optimism Rating of 0.16” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/01/15/west-pharmaceutical-services-wst-receives-coverage-optimism-rating-of-0-16.html.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Stock Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related stocks with our FREE daily email newsletter.